Lv2
120 积分 2024-10-28 加入
Innovative antibody therapeutic development in China compared with the USA and Europe
23天前
已关闭
Rethinking Survival Metrics in EGFR-Mutated NSCLC: Insights from RMST Analysis of FLAURA2 and MARIPOSA
1个月前
已关闭
Safety of osimertinib in Chinese patients with non-small cell lung cancer: a multi-center, prospective, observational study
1个月前
已完结
Current Controversies and Challenges in Non–Oncogene-Addicted Synchronous Oligometastatic Non–Small Cell Lung Cancer
1个月前
已完结
Echoes of the Past: Radiation Recall Pneumonitis Following Extrapulmonary Radiation Therapy
1个月前
已完结
Neoadjuvant Chemoimmunotherapy in Stage III Non–Small Cell Lung Cancer
1个月前
已关闭
Echoes of the Past: Radiation Recall Pneumonitis Following Extrapulmonary Radiation Therapy
1个月前
已关闭
Genomic characteristics of PD-L1-Induced resistance to EGFR-TKIs in lung adenocarcinoma
2个月前
已完结
Immunological features of clear-cell renal-cell carcinoma and resistance to immune checkpoint inhibitors
4个月前
已完结
A single-cell map of patients with non-small cell lung cancer harboring rare-driver mutations after anti-PD-1 treatment
5个月前
已完结
皖公网安备34019202002308
